Pub Date : 2024-12-20DOI: 10.5662/wjm.v14.i4.93559
Michael Colwill, Richard Pollok, Andrew Poullis
Research surveys are believed to have originated in antiquity with evidence of them being performed in ancient Egypt and Greece. In the past century, their use has grown significantly and they are now one of the most frequently employed research methods including in the field of healthcare. Modern validation techniques and processes have allowed researchers to broaden the scope of qualitative data they can gather through these surveys such as an individual's views on service quality to nationwide surveys that are undertaken regularly to follow healthcare trends. This article focuses on the evolution and current utility of research surveys, different methodologies employed in their creation, the advantages and disadvantages of different forms and their future use in healthcare research. We also review the role artificial intelligence and the importance of increased patient participation in the development of these surveys in order to obtain more accurate and clinically relevant data.
{"title":"Research surveys and their evolution: Past, current and future uses in healthcare.","authors":"Michael Colwill, Richard Pollok, Andrew Poullis","doi":"10.5662/wjm.v14.i4.93559","DOIUrl":"10.5662/wjm.v14.i4.93559","url":null,"abstract":"<p><p>Research surveys are believed to have originated in antiquity with evidence of them being performed in ancient Egypt and Greece. In the past century, their use has grown significantly and they are now one of the most frequently employed research methods including in the field of healthcare. Modern validation techniques and processes have allowed researchers to broaden the scope of qualitative data they can gather through these surveys such as an individual's views on service quality to nationwide surveys that are undertaken regularly to follow healthcare trends. This article focuses on the evolution and current utility of research surveys, different methodologies employed in their creation, the advantages and disadvantages of different forms and their future use in healthcare research. We also review the role artificial intelligence and the importance of increased patient participation in the development of these surveys in order to obtain more accurate and clinically relevant data.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"93559"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-20DOI: 10.5662/wjm.v14.i4.95598
Yazan Abboud, Raj Malhotra, Muhammad Hassaan Arif Maan, Anna Mathew, Ibrahim Abboud, Chun-Wei Pan, Saqr Alsakarneh, Fouad Jaber, Islam Mohamed, David Kim, Nikolaos T Pyrsopoulos
Background: While prior data showed an increasing incidence of hepatocellular carcinoma (HCC) in the United States, there are limited comprehensive and comparative data on the geographical variations of HCC trends in different demographic-specific populations.
Aim: To evaluate sex and age-specific incidence rates and time trends in different geographical regions in the United States.
Methods: Age-adjusted HCC incidence rates were collected from the United States Cancer Statistics (USCS) database which covers approximately 98% of the population in the United States. HCC rates were stratified by sex, age, and geographical region. annual percentage change (APC) and average APC (AAPC) were estimated using Joinpoint Regression. A pairwise comparison was conducted between sex-specific trends.
Results: There were 467344 patients diagnosed with HCC in the United States in the USCS database between 2001 and 2020. The rates and trends varied by geographical region. When looking at the West region (115336 patients), incidence rates of HCC were overall increasing and also increasing in older adults. However, when evaluating younger adults, HCC incidence rates decreased in men but not in women with a sex-specific absolute AAPC-difference of 2.15 (P = 0.005). When evaluating the Midwest region (84612 patients), similar results were seen. While incidence rates were increasing in the overall population and in older adults as well, they were decreasing in younger men but not in women with a sex-specific absolute AAPC-difference of 1.61 (P < 0.001). For the Northeast region (87259 patients), the analysis showed similar results with decreasing HCC incidence rates in younger men but not counterpart women (Sex-specific AAPC-difference = 3.26, P < 0.001). Lastly, when evaluating the south (180137 patients), the results were also decreasing in younger men but not in women (Sex-specific AAPC-difference = 2.55, P < 0.001).
Conclusion: Nationwide analysis covering around 98% of the United States population shows an increasing incidence of HCC across all geographical regions, most notably in the South. While younger men experienced decreasing HCC incidence, younger women had a stable trend and this was noted across all regions as well. Our study offers insight into the epidemiology of HCC in different demographic groups across various United States geographical regions. While the reasons contributing to our findings are unclear, they can be related to sex and regional disparities in healthcare access and utilization. Future research is warranted to characterize the temporal change in HCC risk factors across different United States regions.
{"title":"Hepatocellular carcinoma national burden across different geographical regions in the United States between 2001 and 2020.","authors":"Yazan Abboud, Raj Malhotra, Muhammad Hassaan Arif Maan, Anna Mathew, Ibrahim Abboud, Chun-Wei Pan, Saqr Alsakarneh, Fouad Jaber, Islam Mohamed, David Kim, Nikolaos T Pyrsopoulos","doi":"10.5662/wjm.v14.i4.95598","DOIUrl":"10.5662/wjm.v14.i4.95598","url":null,"abstract":"<p><strong>Background: </strong>While prior data showed an increasing incidence of hepatocellular carcinoma (HCC) in the United States, there are limited comprehensive and comparative data on the geographical variations of HCC trends in different demographic-specific populations.</p><p><strong>Aim: </strong>To evaluate sex and age-specific incidence rates and time trends in different geographical regions in the United States.</p><p><strong>Methods: </strong>Age-adjusted HCC incidence rates were collected from the United States Cancer Statistics (USCS) database which covers approximately 98% of the population in the United States. HCC rates were stratified by sex, age, and geographical region. annual percentage change (APC) and average APC (AAPC) were estimated using Joinpoint Regression. A pairwise comparison was conducted between sex-specific trends.</p><p><strong>Results: </strong>There were 467344 patients diagnosed with HCC in the United States in the USCS database between 2001 and 2020. The rates and trends varied by geographical region. When looking at the West region (115336 patients), incidence rates of HCC were overall increasing and also increasing in older adults. However, when evaluating younger adults, HCC incidence rates decreased in men but not in women with a sex-specific absolute AAPC-difference of 2.15 (<i>P</i> = 0.005). When evaluating the Midwest region (84612 patients), similar results were seen. While incidence rates were increasing in the overall population and in older adults as well, they were decreasing in younger men but not in women with a sex-specific absolute AAPC-difference of 1.61 (<i>P</i> < 0.001). For the Northeast region (87259 patients), the analysis showed similar results with decreasing HCC incidence rates in younger men but not counterpart women (Sex-specific AAPC-difference = 3.26, <i>P</i> < 0.001). Lastly, when evaluating the south (180137 patients), the results were also decreasing in younger men but not in women (Sex-specific AAPC-difference = 2.55, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Nationwide analysis covering around 98% of the United States population shows an increasing incidence of HCC across all geographical regions, most notably in the South. While younger men experienced decreasing HCC incidence, younger women had a stable trend and this was noted across all regions as well. Our study offers insight into the epidemiology of HCC in different demographic groups across various United States geographical regions. While the reasons contributing to our findings are unclear, they can be related to sex and regional disparities in healthcare access and utilization. Future research is warranted to characterize the temporal change in HCC risk factors across different United States regions.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95598"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-20DOI: 10.5662/wjm.v14.i4.91387
Michael Colwill, Samantha Baillie, Richard Pollok, Andrew Poullis
The importance and utility of biobanks has increased exponentially since their inception and creation. Initially used as part of translational research, they now contribute over 40% of data for all cancer research papers in the United States of America and play a crucial role in all aspects of healthcare. Multiple classification systems exist but a simplified approach is to either classify as population-based or disease-oriented entities. Whilst historically publicly funded institutions, there has been a significant increase in industry funded entities across the world which has changed the dynamic of biobanks offering new possibilities but also new challenges. Biobanks face legal questions over data sharing and intellectual property as well as ethical and sustainability questions particularly as the world attempts to move to a low-carbon economy. International collaboration is required to address some of these challenges but this in itself is fraught with complexity and difficulty. This review will examine the current utility of biobanks in the modern healthcare setting as well as the current and future challenges these vital institutions face.
{"title":"Biobanks and biomarkers: Their current and future role in biomedical research.","authors":"Michael Colwill, Samantha Baillie, Richard Pollok, Andrew Poullis","doi":"10.5662/wjm.v14.i4.91387","DOIUrl":"10.5662/wjm.v14.i4.91387","url":null,"abstract":"<p><p>The importance and utility of biobanks has increased exponentially since their inception and creation. Initially used as part of translational research, they now contribute over 40% of data for all cancer research papers in the United States of America and play a crucial role in all aspects of healthcare. Multiple classification systems exist but a simplified approach is to either classify as population-based or disease-oriented entities. Whilst historically publicly funded institutions, there has been a significant increase in industry funded entities across the world which has changed the dynamic of biobanks offering new possibilities but also new challenges. Biobanks face legal questions over data sharing and intellectual property as well as ethical and sustainability questions particularly as the world attempts to move to a low-carbon economy. International collaboration is required to address some of these challenges but this in itself is fraught with complexity and difficulty. This review will examine the current utility of biobanks in the modern healthcare setting as well as the current and future challenges these vital institutions face.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"91387"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-20DOI: 10.5662/wjm.v14.i4.95904
Vakaola I Pulotu Mafi, Jonathan Soldera
Background: End stage liver disease (ESLD) represents a growing health concern characterized by elevated morbidity and mortality, particularly among individual ineligible for liver transplantation. The demand for palliative care (PC) is pronounced in patients grappling with ESLD and acute on chronic liver failure (ACLF). Unfortunately, the historical underutilization of PC in ESLD patients, despite their substantial needs and those of their family caregivers, underscores the imperative of seamlessly integrating PC principles into routine healthcare practices across the entire disease spectrum.
Aim: To comprehensively investigate the evidence surrounding the benefits of incorporating PC into the comprehensive care plan for individuals confronting ESLD and/or ACLF.
Methods: A systematic search in the Medline (PubMed) database was performed using a predetermined search command, encompassing studies published in English without any restrictions on the publication date. Subsequently, the retrieved studies were manually examined. Simple descriptive analyses were employed to summarize the results.
Results: The search strategies yielded 721 references. Following the final analysis, 32 full-length references met the inclusion criteria and were consequently incorporated into the study. Meticulous data extraction from these 32 studies was undertaken, leading to the execution of a comprehensive narrative systematic review. The review found that PC provides significant benefits, reducing symptom burden, depressive symptoms, readmission rates, and hospital stays. Yet, barriers like the appeal of transplants and misconceptions about PC hinder optimal utilization. Integrating PC early, upon the diagnosis of ESLD and ACLF, regardless of transplant eligibility and availability, improves the quality of life for these patients.
Conclusion: Despite the substantial suffering and poor prognosis associated with ESLD and ACLF, where liver transplantation stands as the only curative treatment, albeit largely inaccessible, PC services have been overtly provided too late in the course of the illness. A comprehensive understanding of PC's pivotal role in treating ESLD and ACLF is crucial for overcoming these barriers, involving healthcare providers, patients, and caregivers.
{"title":"Palliative care for end-stage liver disease and acute on chronic liver failure: A systematic review.","authors":"Vakaola I Pulotu Mafi, Jonathan Soldera","doi":"10.5662/wjm.v14.i4.95904","DOIUrl":"10.5662/wjm.v14.i4.95904","url":null,"abstract":"<p><strong>Background: </strong>End stage liver disease (ESLD) represents a growing health concern characterized by elevated morbidity and mortality, particularly among individual ineligible for liver transplantation. The demand for palliative care (PC) is pronounced in patients grappling with ESLD and acute on chronic liver failure (ACLF). Unfortunately, the historical underutilization of PC in ESLD patients, despite their substantial needs and those of their family caregivers, underscores the imperative of seamlessly integrating PC principles into routine healthcare practices across the entire disease spectrum.</p><p><strong>Aim: </strong>To comprehensively investigate the evidence surrounding the benefits of incorporating PC into the comprehensive care plan for individuals confronting ESLD and/or ACLF.</p><p><strong>Methods: </strong>A systematic search in the Medline (PubMed) database was performed using a predetermined search command, encompassing studies published in English without any restrictions on the publication date. Subsequently, the retrieved studies were manually examined. Simple descriptive analyses were employed to summarize the results.</p><p><strong>Results: </strong>The search strategies yielded 721 references. Following the final analysis, 32 full-length references met the inclusion criteria and were consequently incorporated into the study. Meticulous data extraction from these 32 studies was undertaken, leading to the execution of a comprehensive narrative systematic review. The review found that PC provides significant benefits, reducing symptom burden, depressive symptoms, readmission rates, and hospital stays. Yet, barriers like the appeal of transplants and misconceptions about PC hinder optimal utilization. Integrating PC early, upon the diagnosis of ESLD and ACLF, regardless of transplant eligibility and availability, improves the quality of life for these patients.</p><p><strong>Conclusion: </strong>Despite the substantial suffering and poor prognosis associated with ESLD and ACLF, where liver transplantation stands as the only curative treatment, albeit largely inaccessible, PC services have been overtly provided too late in the course of the illness. A comprehensive understanding of PC's pivotal role in treating ESLD and ACLF is crucial for overcoming these barriers, involving healthcare providers, patients, and caregivers.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95904"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Medication errors, especially in dosage calculation, pose risks in healthcare. Artificial intelligence (AI) systems like ChatGPT and Google Bard may help reduce errors, but their accuracy in providing medication information remains to be evaluated.
Aim: To evaluate the accuracy of AI systems (ChatGPT 3.5, ChatGPT 4, Google Bard) in providing drug dosage information per Harrison's Principles of Internal Medicine.
Methods: A set of natural language queries mimicking real-world medical dosage inquiries was presented to the AI systems. Responses were analyzed using a 3-point Likert scale. The analysis, conducted with Python and its libraries, focused on basic statistics, overall system accuracy, and disease-specific and organ system accuracies.
Results: ChatGPT 4 outperformed the other systems, showing the highest rate of correct responses (83.77%) and the best overall weighted accuracy (0.6775). Disease-specific accuracy varied notably across systems, with some diseases being accurately recognized, while others demonstrated significant discrepancies. Organ system accuracy also showed variable results, underscoring system-specific strengths and weaknesses.
Conclusion: ChatGPT 4 demonstrates superior reliability in medical dosage information, yet variations across diseases emphasize the need for ongoing improvements. These results highlight AI's potential in aiding healthcare professionals, urging continuous development for dependable accuracy in critical medical situations.
{"title":"Comparative evaluation of artificial intelligence systems' accuracy in providing medical drug dosages: A methodological study.","authors":"Swaminathan Ramasubramanian, Sangeetha Balaji, Tejashri Kannan, Naveen Jeyaraman, Shilpa Sharma, Filippo Migliorini, Suhasini Balasubramaniam, Madhan Jeyaraman","doi":"10.5662/wjm.v14.i4.92802","DOIUrl":"10.5662/wjm.v14.i4.92802","url":null,"abstract":"<p><strong>Background: </strong>Medication errors, especially in dosage calculation, pose risks in healthcare. Artificial intelligence (AI) systems like ChatGPT and Google Bard may help reduce errors, but their accuracy in providing medication information remains to be evaluated.</p><p><strong>Aim: </strong>To evaluate the accuracy of AI systems (ChatGPT 3.5, ChatGPT 4, Google Bard) in providing drug dosage information per Harrison's Principles of Internal Medicine.</p><p><strong>Methods: </strong>A set of natural language queries mimicking real-world medical dosage inquiries was presented to the AI systems. Responses were analyzed using a 3-point Likert scale. The analysis, conducted with Python and its libraries, focused on basic statistics, overall system accuracy, and disease-specific and organ system accuracies.</p><p><strong>Results: </strong>ChatGPT 4 outperformed the other systems, showing the highest rate of correct responses (83.77%) and the best overall weighted accuracy (0.6775). Disease-specific accuracy varied notably across systems, with some diseases being accurately recognized, while others demonstrated significant discrepancies. Organ system accuracy also showed variable results, underscoring system-specific strengths and weaknesses.</p><p><strong>Conclusion: </strong>ChatGPT 4 demonstrates superior reliability in medical dosage information, yet variations across diseases emphasize the need for ongoing improvements. These results highlight AI's potential in aiding healthcare professionals, urging continuous development for dependable accuracy in critical medical situations.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"92802"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In the realm of orthopedics, the adoption of enhanced recovery after surgery (ERAS) protocols marks a significant stride towards enhancing patient well-being. By embracing a holistic approach that encompasses preoperative counseling, dietary optimization, minimally invasive procedures, and early postoperative mobilization, these protocols have ushered in a new era of surgical care. Despite encountering hurdles like resistance to change and resource allocation challenges, the efficacy of ERAS protocols in improving clinical outcomes is undeniable. Noteworthy benefits include shortened hospital stays and bolstered improved patient-safety measures. Looking ahead, the horizon for ERAS in orthopedics appears bright, with an emphasis on tailoring care to individual needs, integrating cutting-edge technologies, and perpetuating research endeavors. This shift towards a more personalized, streamlined, and cost-efficient model of care underscores the transformative potential of ERAS in reshaping not only orthopedic surgery but also the journey to patient recovery. This editorial details the scope and future of ERAS in the orthopedic specialty.
{"title":"Optimizing outcomes: Implementing enhanced recovery after surgery in orthopedic surgery.","authors":"Sathish Muthu, Madhan Jeyaraman, Naveen Jeyaraman, Swaminathan Ramasubramanian","doi":"10.5662/wjm.v14.i4.95558","DOIUrl":"10.5662/wjm.v14.i4.95558","url":null,"abstract":"<p><p>In the realm of orthopedics, the adoption of enhanced recovery after surgery (ERAS) protocols marks a significant stride towards enhancing patient well-being. By embracing a holistic approach that encompasses preoperative counseling, dietary optimization, minimally invasive procedures, and early postoperative mobilization, these protocols have ushered in a new era of surgical care. Despite encountering hurdles like resistance to change and resource allocation challenges, the efficacy of ERAS protocols in improving clinical outcomes is undeniable. Noteworthy benefits include shortened hospital stays and bolstered improved patient-safety measures. Looking ahead, the horizon for ERAS in orthopedics appears bright, with an emphasis on tailoring care to individual needs, integrating cutting-edge technologies, and perpetuating research endeavors. This shift towards a more personalized, streamlined, and cost-efficient model of care underscores the transformative potential of ERAS in reshaping not only orthopedic surgery but also the journey to patient recovery. This editorial details the scope and future of ERAS in the orthopedic specialty.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95558"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Point-of-care ultrasound (POCUS) is a limited ultrasound examination performed by the clinician at the bedside, emerging as a complement to physical examination across various medical specialties. In the field of nephrology, its integration has been gradual, primarily limited to guiding procedures like temporary dialysis catheter placement or, in some cases, diagnostic kidney ultrasounds. In reality, the assessment of hemodynamic status at the bedside holds immense value for nephrologists, yet there exists limited awareness among practitioners regarding its implementation. While there is a growing trend towards incorporating multi-organ POCUS training in fellowship programs, private practice nephrologists remain relatively uninformed. This discussion explores the untapped potential of POCUS as a valuable diagnostic tool in everyday nephrology practice, demonstrating its effectiveness in diverse clinical settings, ranging from medical wards to outpatient dialysis units. Additionally, we delve into the challenges hindering its widespread adoption and consider the future trajectory of this innovative approach.
{"title":"Point-of-care ultrasound in nephrology: A private practice viewpoint.","authors":"Rajiv Sinanan, Afsheen Moshtaghi, Abhilash Koratala","doi":"10.5662/wjm.v14.i4.95685","DOIUrl":"10.5662/wjm.v14.i4.95685","url":null,"abstract":"<p><p>Point-of-care ultrasound (POCUS) is a limited ultrasound examination performed by the clinician at the bedside, emerging as a complement to physical examination across various medical specialties. In the field of nephrology, its integration has been gradual, primarily limited to guiding procedures like temporary dialysis catheter placement or, in some cases, diagnostic kidney ultrasounds. In reality, the assessment of hemodynamic status at the bedside holds immense value for nephrologists, yet there exists limited awareness among practitioners regarding its implementation. While there is a growing trend towards incorporating multi-organ POCUS training in fellowship programs, private practice nephrologists remain relatively uninformed. This discussion explores the untapped potential of POCUS as a valuable diagnostic tool in everyday nephrology practice, demonstrating its effectiveness in diverse clinical settings, ranging from medical wards to outpatient dialysis units. Additionally, we delve into the challenges hindering its widespread adoption and consider the future trajectory of this innovative approach.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95685"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-20DOI: 10.5662/wjm.v14.i4.95210
Arkiath Veettil Raveendran
The remission of type 2 diabetes mellitus (T2DM) is a topic that has been widely discussed recently, and it gives new hope for people with T2DM. Achievement of normal blood glucose levels or levels below the diagnostic threshold for T2DM without pharmacotherapy among people with T2DM after metabolic surgery and carbohydrate or calorie-restricted diet paved the way for more enthusiastic research in this area. There is a lot of confusion regarding the appropriate terminology and definition of remission of T2DM. In this short review, we briefly analyzed the emerging concepts and proposed criteria for diagnosing remission of T2DM, which will be helpful for healthcare providers and people with T2DM.
{"title":"Remission of type 2 diabetes mellitus: Emerging concepts and proposed diagnostic criteria.","authors":"Arkiath Veettil Raveendran","doi":"10.5662/wjm.v14.i4.95210","DOIUrl":"10.5662/wjm.v14.i4.95210","url":null,"abstract":"<p><p>The remission of type 2 diabetes mellitus (T2DM) is a topic that has been widely discussed recently, and it gives new hope for people with T2DM. Achievement of normal blood glucose levels or levels below the diagnostic threshold for T2DM without pharmacotherapy among people with T2DM after metabolic surgery and carbohydrate or calorie-restricted diet paved the way for more enthusiastic research in this area. There is a lot of confusion regarding the appropriate terminology and definition of remission of T2DM. In this short review, we briefly analyzed the emerging concepts and proposed criteria for diagnosing remission of T2DM, which will be helpful for healthcare providers and people with T2DM.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95210"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diabetes mellitus (DM) is a chronic metabolic non-communicable disease with the ability to cause serious microvascular and macrovascular complications throughout the body, including in the eye. Diabetic retinopathy (DR), present in one-third of patients with diabetes, is a vision-threatening complication caused by uncontrolled diabetes, which greatly affects the retinal blood vessels and the light-sensitive inner retina, eventually leading to blindness. Several epidemiological studies elucidate that DR can vary by age of onset, duration, types of diabetes, and ethnicity. Recent studies show that the pathogenesis of diabetic retinopathy has spread its roots beyond merely being the result of hyperglycemia. The complexity of its etiopathology and diagnosis makes therapeutic intervention challenging. This review throws light on the pathological processes behind DR, the cascade of events that follow it, as well as the available and emerging treatment options.
{"title":"Diabetic retinopathy: A review on its pathophysiology and novel treatment modalities.","authors":"Arvind Kumar Morya, Prasanna Venkatesh Ramesh, Prateek Nishant, Kirandeep Kaur, Bharat Gurnani, Aarti Heda, Sarika Salodia","doi":"10.5662/wjm.v14.i4.95881","DOIUrl":"10.5662/wjm.v14.i4.95881","url":null,"abstract":"<p><p>Diabetes mellitus (DM) is a chronic metabolic non-communicable disease with the ability to cause serious microvascular and macrovascular complications throughout the body, including in the eye. Diabetic retinopathy (DR), present in one-third of patients with diabetes, is a vision-threatening complication caused by uncontrolled diabetes, which greatly affects the retinal blood vessels and the light-sensitive inner retina, eventually leading to blindness. Several epidemiological studies elucidate that DR can vary by age of onset, duration, types of diabetes, and ethnicity. Recent studies show that the pathogenesis of diabetic retinopathy has spread its roots beyond merely being the result of hyperglycemia. The complexity of its etiopathology and diagnosis makes therapeutic intervention challenging. This review throws light on the pathological processes behind DR, the cascade of events that follow it, as well as the available and emerging treatment options.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95881"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
One of the leading causes of cancer-related death is gastrointestinal cancer, which has a significant morbidity and mortality rate. Although preoperative risk assessment is essential for directing patient care, its biological behavior cannot be accurately predicted by conventional imaging investigations. Potential pathophysiological information in anatomical imaging that cannot be visually identified can now be converted into high-dimensional quantitative image features thanks to the developing discipline of molecular imaging. In order to enable molecular tissue profile in vivo, molecular imaging has most recently been utilized to phenotype the expression of single receptors and targets of biological therapy. It is expected that molecular imaging will become increasingly important in the near future, driven by the expanding range of biological therapies for cancer. With this live molecular fingerprinting, molecular imaging can be utilized to drive expression-tailored customized therapy. The technical aspects of molecular imaging are first briefly discussed in this review, followed by an examination of the most recent research on the diagnosis, prognosis, and potential future clinical methods of molecular imaging for GI tract malignancies.
{"title":"Role of molecular imaging in prognosis, diagnosis, and treatment of gastrointestinal cancers: An update on new therapeutic methods.","authors":"Mobina Fathi, Hayder Jasim Taher, Sabah Jassim Al-Rubiae, Shirin Yaghoobpoor, Ashkan Bahrami, Reza Eshraghi, Hossein Sadri, Mahsa Asadi Anar, Ali Gholamrezanezhad","doi":"10.5662/wjm.v14.i4.93461","DOIUrl":"10.5662/wjm.v14.i4.93461","url":null,"abstract":"<p><p>One of the leading causes of cancer-related death is gastrointestinal cancer, which has a significant morbidity and mortality rate. Although preoperative risk assessment is essential for directing patient care, its biological behavior cannot be accurately predicted by conventional imaging investigations. Potential pathophysiological information in anatomical imaging that cannot be visually identified can now be converted into high-dimensional quantitative image features thanks to the developing discipline of molecular imaging. In order to enable molecular tissue profile <i>in vivo</i>, molecular imaging has most recently been utilized to phenotype the expression of single receptors and targets of biological therapy. It is expected that molecular imaging will become increasingly important in the near future, driven by the expanding range of biological therapies for cancer. With this live molecular fingerprinting, molecular imaging can be utilized to drive expression-tailored customized therapy. The technical aspects of molecular imaging are first briefly discussed in this review, followed by an examination of the most recent research on the diagnosis, prognosis, and potential future clinical methods of molecular imaging for GI tract malignancies.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"93461"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}